MedTrace Logo

A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks

NCT00719914 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2012-08-27

Study results available
· View outcomes & findings →

Summary

The main purpose of this research study is to try to improve the results of the standard treatment for heart attacks. Normally, heart attack patients get a fast dose and a slow dose of eptifibatide in the emergency room, shortly after arriving. This drug is usually given through a vein in the arm. However, eptifibatide can also be injected directly into the heart's blood supply just before angioplasty, a common procedure to unblock a blood vessel in the heart. This new way of giving the drug is being studying.

Conditions

  • ST-Elevation Myocardial Infarction

Interventions

DRUG

eptifibatide

Intra-coronary injection, weight based, of eptifibatide.

DRUG

eptifibatide

Intra-coronary injection, based on weight, of eptifibatide

DRUG

normal saline

Intra-coronary injection, weight based, of normal saline.

Sponsors & Collaborators

  • Schering-Plough

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Eugene Braunwald, M.D. · The TIMI Study Group

  • C. Michael Gibson, M.D. · The TIMI Study Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-11-30
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719914 on ClinicalTrials.gov